Dendreon stays focused on launch countdown

Dendreon may not have an approval yet for its prostate cancer therapy, but it's acting a lot like it's a done deal. In the last two days, Dendreon has raised $356 million from a stock sale and hired Bayer HealthCare veteran Hans Bishop as its COO. Bishop will be in charge of manufacturing. Story | Report